Q1 2024 EPS Estimates for bluebird bio, Inc. (NASDAQ:BLUE) Cut by Wedbush

bluebird bio, Inc. (NASDAQ:BLUE) – Research analysts at Wedbush dropped their Q1 2024 earnings per share (EPS) estimates for shares of bluebird bio in a report issued on Tuesday, March 26th. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($0.69) per share for the quarter, down from their previous forecast of ($0.62). Wedbush currently has a “Neutral” rating and a $1.68 target price on the stock. The consensus estimate for bluebird bio’s current full-year earnings is ($1.78) per share. Wedbush also issued estimates for bluebird bio’s Q2 2024 earnings at ($0.69) EPS, Q3 2024 earnings at ($0.58) EPS, Q4 2024 earnings at ($0.50) EPS, FY2024 earnings at ($2.45) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.90) EPS, FY2026 earnings at ($0.57) EPS and FY2028 earnings at ($0.09) EPS.

A number of other equities research analysts have also recently commented on BLUE. Royal Bank of Canada reissued a “sector perform” rating and set a $6.00 price target on shares of bluebird bio in a report on Wednesday. Bank of America cut their target price on shares of bluebird bio from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, December 21st. StockNews.com upgraded bluebird bio to a “sell” rating in a research report on Thursday. Robert W. Baird lowered their target price on bluebird bio from $10.00 to $7.00 and set an “outperform” rating for the company in a research report on Tuesday, December 12th. Finally, Wells Fargo & Company decreased their price target on shares of bluebird bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Two analysts have rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.87.

bluebird bio Price Performance

BLUE opened at $1.28 on Thursday. bluebird bio has a 1-year low of $0.88 and a 1-year high of $5.53. The company has a 50 day simple moving average of $1.24 and a two-hundred day simple moving average of $2.27. The firm has a market cap of $139.96 million, a P/E ratio of -1.73 and a beta of 0.75.

Institutional Investors Weigh In On bluebird bio

Several large investors have recently modified their holdings of BLUE. US Bancorp DE grew its position in shares of bluebird bio by 885.7% in the 2nd quarter. US Bancorp DE now owns 7,511 shares of the biotechnology company’s stock worth $25,000 after buying an additional 6,749 shares during the last quarter. Raymond James & Associates purchased a new stake in shares of bluebird bio during the 1st quarter valued at $50,000. Stifel Financial Corp acquired a new stake in shares of bluebird bio in the 3rd quarter worth $32,000. Penserra Capital Management LLC purchased a new position in bluebird bio during the 1st quarter worth $53,000. Finally, Aigen Investment Management LP acquired a new position in bluebird bio during the 3rd quarter valued at about $34,000. Institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.